Press Releases May 13, 2026 07:30 AM

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Dyne Therapeutics to present at multiple upcoming 2026 investor healthcare conferences

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
DYN

Dyne Therapeutics, a clinical-stage biopharmaceutical company focused on genetically driven neuromuscular diseases, announced its management team's participation in three major 2026 investor healthcare conferences with live fireside chats and meetings. The company is advancing clinical and preclinical programs for diseases including Duchenne muscular dystrophy and myotonic dystrophy type 1.

Dyne Therapeutics to Participate in Upcoming Investor Conferences
DYN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Dyne Therapeutics will participate in RBC Capital Markets, Jefferies Global Healthcare, and Goldman Sachs Annual Global Healthcare Conferences in May and June 2026.
  • The company focuses on developing therapeutics targeting muscle and CNS to treat genetically driven neuromuscular diseases such as DMD and DM1.
  • Live webcasts and replays of the presentations will be available, increasing transparency and investor access.

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:

  • 2026 RBC Capital Markets Global Healthcare Conference, fireside chat on Wednesday, May 20, 2026 at 11:00 a.m. ET in New York, NY
  • 2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 9:55 a.m. ET in New York, NY
  • Goldman Sachs 47th Annual Global Healthcare Conference 2026, hosting meetings on Tuesday, June 9, 2026 in Miami, FL

A live webcast of each fireside chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:

Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker 
snartker@dyne-tx.com
781-317-1938


Risks

  • Conference participation may not immediately translate to clinical or commercial progress, which could limit short-term stock impact.
  • The development programs are at clinical or preclinical stages, carrying normal risks of trial outcomes and regulatory approvals.
  • Investor interest and perception may fluctuate based on the information presented and broader biotech market conditions.

More from Press Releases

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026